He has difficulty swallowing, speaking, and weakness of neck flexors, extensors and deltoids.
He was admitted two weeks prior to admission and was discharged on the Saturday prior to admission for treatment of his myasthenia [**Last Name (un) 2902**].
During that admission, he was plasmapheresed, given prednisone 40 mg p.o.
q.o.d., CellCept 1,000 mg p.o.
and Mestinon 30 mg p.o.
Benign prostatic hypertrophy, status post transurethral resection of the prostate.
Flomax 0.4 mg p.o.
Zocor 40 mg p.o.
Lisinopril 10 mg p.o.
Glucovance 2.5/500 mg tablets one tablet p.o.
Mestinon 30 mg p.o.
Protonix 40 mg p.o.
CellCept 1,000 mg p.o.
Prednisone 40 mg p.o.
Insulin sliding scale.
He has prominent dysphonia and dysphagia for solids and liquids.
He was given initially Mestinon 45 mg p.o.
His prednisone was discontinued and Solu-Medrol at a dose of 250 mg IV was instituted.
His insulin sliding scale was continued.
Because the patient could not take oral medication, he was given neostigmine 1-2 mm subcutaneously in order to be able to swallow his Mestinon.
He also received vital capacities and nebulizers q. four hours.
On hospital day number two, his Mestinon was changed to 45, 60, 60, 45.
The prednisone was discontinued on [**2137-6-7**] under the recommendations of the Neuromuscular consultation service.
His prednisone was changed to 60 mg p.o.
This resulted in improvement in his strength, particularly with his voice and with his swallowing.
The patient has had a successful course of treatment for myasthenic crisis and because his muscle strength improved back to baseline, the decision was made to discharge him home on [**2137-6-18**].
Prednisone 60 mg p.o.
Pepcid 20 mg p.o.
Flomax 0.4 mg p.o.
Zocor 40 mg p.o.
Glucovance 2.5 500 mg tablets one tablet p.o.
Insulin sliding scale; 0-200 give 0 units of regular insulin; 201-250 give 2 units; 251-300 give 4 units; 301-350 give 6 units; 351 plus give 8 units.
Mestinon 30 mg p.o.
He has received definitive treatment for myasthenia [**Last Name (un) 2902**].
